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Abstract 
Arteriovenous malformations are congenital lesions that occur most commonly in the 
supratentorial region. These space-occupying vascular lesions consist of multiple arteries and 
veins, connecting as a fistula without an intervening normal capillary bed. Typically, AVM’s are 
single lesions, except when associated with hereditary hemorrhagic telangiectasia. The histology 
includes clusters of normal or dilated arteries and abnormal veins with calcification and 
occasionally some prior haemorrhage. 
Keywords: grading, hemorrhage, re haemorrhage, seizures, unruptured arteriovenous 
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Introduction 
Arteriovenous malformations (AVM) 
of the brain are congenital vascular lesions 
that account for approximately 2%- 3% of 
all hemorrhagic strokes[1]. Despite the 
relative rarity of the disease (with an 
estimated current detection rate of 
approximately 1/100 000 person-years) 
AVMs pose a significant neurological 
problem because patients are mostly 
young and otherwise healthy. Moreover, 
the availability of noninvasive imaging has 
rapidly increased the detection of 
incidental AVM’s. The complex 
cerebrovascular anatomy of AVM’s makes 
them a challenge to treat, and the 
treatment itself carries significant risks.  
To evaluate the possible benefit of a 
risky treatment, one needs to understand 
the natural history and prognosis of the 
disease. The complexity of AVM’s makes 
them a rather heterogeneous group of 
lesions in terms of various factors possibly 
affecting the risk of rupture and 
subsequent hemorrhagic stroke. Over the 
past several decades, several groups have 
contributed to our knowledge of the 
haemorrhage risk associated with 
untreated AVM’s. However, the 
development of therapeutic strategies has 
made it increasingly rare that a large 
proportion of patients would be followed 
conservatively. 
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Clinical Presentation 
The most common presentation in 
unruptured AVM’s is focal or generalized 
seizures, which occur in 25% of patients. 
Other presentations include headache in 
15% of patients, which may mimic 
migraine, focal neurologic deficit, and 
pulsatile tinnitus. Rarely, a deficit may be 
caused by a “steal” phenomenon of blood 
through the fistula, which deprives some 
surrounding neurons of required blood. 
The lesions are distinctly uncommon in 
children; presentations include congestive 
heart failure and large head due to 
hydrocephalus.  
Headache not due to hemorrhage is 
the presenting symptom in 7% to 48% of 
patients [11]. No distinctive type, 
frequency, persistence, or severity occurs. 
Earlier speculations have proved 
unfounded for a pattern differentiated 
from classical or common migraine, or 
that recurrent unilateral headache reflects 
an underlying AVM [12]. Response to 
medication has not been systematically 
studied, and although some 
reports state improvement in headache 
[13], proof is lacking that patients under 
optimal medical headache management 
require invasive treatment of their 
symptoms. Some reference to focal 
neurologic deficits without signs of 
underlying hemorrhage has been reported 
in 1% to 40%, with this large range 
reflecting non uniformity of definitions. 
Only a few patients (4% to 8%) have well 
documented progressing neurologic 
deficits [11]. Once considered common, 
progressing syndromes were thought 
to be caused by “stealing” (ie, cerebral 
artery hypotension leading to ischemia in 
brain tissue adjacent to the lesion) 
[14,15]. Arteriovenous malformations 
sometimes induce remarkable degrees of 
cerebral arterial hypotension, but 
evidence is lacking for a causal link with 
symptoms[11]. As of today, no definite 
information exists that may warrant 
invasive AVM treatment on the 
assumption of a clinical relevant 
intracranial steal caused by an unruptured 
AVM [16]. Venous hypertension or mass 
effect of the nidus offers alternative 
explanations for progressing focal 
neurologic deficits [17]. 
The natural history of unruptured 
AVM’s seems more favorable than for 
those discovered after initial 
haemorrhage. The average risk of 
bleeding from an unruptured AVM (1.2% 
per year) seems to be about 5 times lower 
as compared with already ruptured 
malformations (5.6% per year). The 
bleeding risk seems to be particularly low 
in the most frequent subgroup of patients 
harbouring lobar AVMs with superficial 
venous drainage (0.9%peryear). Finally, 
although some instances of AVM rupture 
may indeed be disastrous, there seems to 
be a far lower morbidity and mortality 
than after intracerebral bleeding from 
other causes. 
Haemorrhage: Peak age for 
haemorrhage is between age of 15 -20 yrs 
with a mortality of 10% & a morbidity of 
30 -50 % from each bleed. Haemorrhage 
was related to AVM size with small 
AVM’s presenting more often with bleed 
than do large ones. Larger AVM’s more 
often presented with seizures merely 
because of involvement of the cortex. So 
conclusion is that small AVM’s are more 
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lethal than larger ones. Among patients 
who present with haemorrhage, the risk 
of recurrent haemorrhage is elevated 
early; the risk during the first year is 
between 6% and 17% and then decreases 
to a baseline level by the third year. After 
a second haemorrhage, the risk of another 
recurrent haemorrhage maybe even 
higher during the first year, up to 
25%.Clinical and imaging features at the 
time of initial diagnosis of an AVM may 
predict future haemorrhage risk. From a 
clinical standpoint, prior haemorrhage is a 
strong predictor of haemorrhage. On 
imaging, small AVM diameter or small 
volume may be predictive, but this has 
not been noted consistently. The venous 
drainage system may be particularly 
important, with deep venous drainage a 
potential predictor of haemorrhage. 
Impaired venous drainage and a single 
draining vein also have been predictive of 
hemorrhage. In the arterial system of the 
periventricular or intraventricular area, 
the risk of haemorrhage may be increased 
by the presence of very distal aneurysms 
on the small feeding arteries (the so-called 
intranidal aneurysms), the presence of 
multiple aneurysms, and arterial supply 
via middle cerebral artery perforators. 
 The presence of any non-nidal 
aneurysms also may increase the risk of 
haemorrhage. 
Developments in the field of genetic 
research and biomarkers,with the goal of 
identifying patients with increased AVM 
hemorrhage risk, are ongoing. Initial 
results show associations of the tumor 
necrosis factor (TNF)--238 AG 
genotype [35 ], the interleukin (IL)-6-
174GG genotype with high expression of 
IL-6 protein in brain AVM tissue [36], 
and an abnormal balance of matrix 
metalloproteinase (MMP)-9 and tissue 
inhibitors of metalloproteinases (TIMP) 
in the AVM with increased probability of 
AVM hemorrhage [37].Whether 
mechanisms involved will be helpful in 
the decision process of AVM treatment 
remains unsettled 
Rebleeding: Rebleeding rate in the first 
year after haemorrhage was 6% in one 
series and 18% in another series. In 
another large series ( ) the annual rate was 
4% regardless of type of presentation.  
Rebleeding rate declined at 2% per year 
after 10 years. 
 
Life Time Risk of Haemorrhage 
Age at Presentation Estimated Years of 
Life 
1% Annual 
Risk 
2 % Annual  
Risk 
3% Annual  
Risk 
0 76 53 78 90 
15 62 46 71 85 
25 52 41 65 79 
35 43 35 58 73 
45 34 29 50 64 
55 25 22 40 53 
65 18 16 30 42 
75 11 10 20 28 
85 6 5.8 11 17 
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Seizures: Seizures not caused by 
hemorrhage are the mode of initial 
presentation in 16% to 53% of cases. 
Grand mal attacks occur in 27% to 35%, 
with the remainder being partialor partial 
complex seizures [51]. Few reports 
document seizure frequency, but 
response to antiepileptic medication 
appears satisfactory [52]. Patients with 
intractable seizures under conservative 
management do exist but data on their 
frequency are scarce. Improvement of 
seizures in over 50% of these patients 
after stereotactic radiotherapy was 
reported in a small recent series [53]. 
The younger the patient at the time of 
diagnosis, higher the risk of developing 
convulsions.  
20 years risk  
Age 10-19 ---- 44% risk 
Age 20-29 ----31% risk 
Age 30-60 ----6% risk 
No AVM found incidentally or 
presenting with neurological deficits 
developed seizures. 
AVM’S and Aneurysms: Fifty eight 
percent of patients with AVM’s have 
aneurysms. 75% of aneurysms are located 
on the major feeding artery. Aneurysms 
also may form within the nidus or on the 
draining veins.  
Categories of aneurysms associated 
with AVM’s: 
 
Type Aneurysm Location 
1 Proximal on ipsilateral major feeding 
artery 
1 A Proximal on major artery related but 
contralateral to AVM 
11 Distal on superficial feeding artery 
111 Proximal or distal on deep feeding 
artery (bizarre ) 
1V On artery unrelated to AVM 
 
Investigations 
Unenhanced Computed Tomography 
has relatively low sensitivity, with 
calcification and hypointensity  
May be visualised; however, with the 
use of contrast enhancement, the 
arteriovenous system may be seen. 
Computed Tomographic Angiography 
[CTA] provides better vascular detail 
than magnetic resonance angiography 
[MRA]. Magnetic resonance imaging 
[MRI] is more sensitive, with findings 
such as flow voids and hemosiderin 
deposition on T1-weighted and 
T2weighted imaging. Magnetic resonance 
angiography (MRA) can provide 
additional information regarding relation 
of AVM to surrounding cerebral 
structures. Additional information can be 
obtained with the use of functional MRI, 
to identify eloquent brain tissue, and 
diffusion-tensor imaging to identify 
different important white matter tracts. 
Angiography remains the standard by 
which to evaluate the architecture of the 
AVM, including presence or absence of 
associated aneurysms, presence or absence 
of venous outflow obstruction, and 
pattern of venous drainage. Three 
dimensional MRA and three dimensional 
angiography may provide additional detail 
to guide interventional treatment. Grading: 
Spetzler - Martin AVM Grading System [20] 
 
Graded Feature Points 
Size 
Small (< 3 cms ) 
Medium (3-6 cms) 
Large (>6 cms ) 
 
 1 
 2 
 3 
Eloquence of adjacent brain 
Non eloquent 
Eloquent 
 
 0 
 1 
Patten of venous drainage 
Superficial only 
Deep 
 
 0 
 1 
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A separate grade 6 is reserved for 
untreatable lesions, (by any means) 
resection of these would almost 
unavoidably be associated with disabling 
deficit or death. 
Discussion  
Patients harbouring brain AVM’s are at 
a life long risk for haemorrhagic stroke, 
the natural history is poorly understood. 
Natural history & predictive features of 
haemorrhage was studied at Toronto 
western hospital On 678 consecutive 
patients & were followed for 1931. 7 
patient years [50]. The rate of 
haemorrhage over long term follow up 
was recorded. 
The impact of baseline clinical & 
radiographic features & partial treatment 
on time to haemorrhage were analyzed 
using survival analysis. neurologic 
outcome after haemorrhage was assessed 
using Glasgow outcome score. 
Haemorrhage risk was 4.61% per year for 
entire cohort, 7.8 % per year for brain 
AVM”s with haemorrhagic presentation 
4.61 % for brain AVM”s with seizure 
presentation, 3.99 % for patients not 
harbouring aneurysms, 6.93 % for 
patients harbouring aneurysms, 5.42 % 
for patients with deep venous drainage. 
Haemorrhagic presentation was 
significant independent predictor of 
future haemorrhage.. Haemorrhage risk 
was unchanged in patient who underwent 
partial arteriovenous embolisation. So 
they concluded that brain AVM”s 
presenting with haemorrhage, deep 
venous drainage, or associated aneurysms 
had twofold likelihood of future 
haemorrhage. So aggressive short term 
management ie; total embolisation / 
microsurgery was suggested for patients 
harbouring high risk lesions & therapeutic 
approaches with longer obliteration times 
targeted at patients harbouring low risk 
natural history of haemorrhage. 
In a study conducted between july 
1997 & 2003, 73 consecutive patients with 
grade IV & grade V AVM”s were 
evaluated prospectively at Barrow 
neurosurgical institute [32].Treatment 
recommendations were classified as 
complete treatment, partial treatment & 
no treatment. Retrospectively 
haemorrhage rates associated with these 
treatment groups were also calculated. In 
the prospective portion of the study 
[intention to treat analysis ], no treatment 
of AVM”s was recommended for 75 % of 
patients and partial treatment for 10 % of 
patients. Aneurysms associated with an 
AVM were obliterated by surgery or 
endovascular treatment in 10 % patients & 
complete surgical removal of AVM for 5% 
of the patients. The overall haemorrhage 
rate for grade IV & grade V AVM”s was 
1.5% per year. The annual risk of 
haemorrhage was 10.4 % among patients 
who previously received incomplete 
treatment compared with patients without 
previous treatment. Hence they 
concluded that haemorrhage risk was 
comparatively less [1.5 % ] for grade IV & 
grade V AVM”s than for grade I to grade 
III AVM”s. So authors recommended no 
treatment be given for grade IV & grade V 
AVM”s. Partial treatment was discouraged 
for the fact that it worsened the natural 
history of an AVM. The authors did not 
support palliative treatment of AVM 
except in specific circumstances of arterial 
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or intranidal aneurysms or progressive 
neurological deficits related to vascular 
steal. Complete treatment was 
recommended for patients with 
progressive neurological deficits caused 
by haemorrhage of the AVM. Relatively 
low combined morbidity & mortality 
rates for grade IV & grade V AVM”s of 17 
% & 22 % respectively was reported.  
Mahesh.V.Jayaraman et al[41] studied 
on 61 patients retrospectively with grade 
IV & grade V AVM”s. They reviewed the 
demographic, angiographic features, 
presenting symptoms & time of all 
haemorrhage events before or after 
treatment initiation. The annual pre-
treatment haemorrhage rate of 10.4 % was 
higher for all patients with 13.9% for 
patients with haemorrhagic presentation 
and 7.3% for patients with non 
haemorrhagic presentation. Post 
treatment haemorrhage rates were 6.1% 
per year for all patients, 5.6% for patients 
presenting with haemorrhage and 6.4% in 
patients with non haemorrhagic 
presentation. Based on this data they 
concluded that grade IV and grade IV 
AVM”s warranted treatment and 
initiation of treatment did not increase 
the risk of haemorrhage. Initiation of 
treatment in haemorrhagic group lowered 
the risk of re haemorrhage to levels with 
those of non haemorrhagic presentation. 
[Patients with grade IV and grade V 
AVM’s with prior haemorrhage are at a 
higher risk of recurrent haemorrhage] 
Risk factors for subsequent 
haemorrhage in patients with cerebral 
arteriovenous malformations was studied 
by S.Yamada et al[38] on 305 consecutive 
patients with AVM’s between 1983 
&2005. Patients were followed up until 
the first haemorrhage, start of any 
treatment or end of 2005. Possible risk 
factors that were investigated included age 
at initial diagnosis, sex, type of initial 
presentation, size and location of AVM, 
nidus and venous drainage pattern. They 
reported an annual bleeding rate in 
haemorrhagic group was 6.8% after 
haemorrhage and the rate decreased in 5 
years to 1.72 %. In the non haemorrhagic 
group  
Annual bleeding rate of 3.12 % was 
reported. Patients presenting with 
headache annual bleeding rate of 6.48% 
was reported and for asymptomatic 
presentation annual bleeding rate was 
6.44%. Conversely patients presenting 
with seizures had an annual bleeding rate 
of 2.20 % and with patients with 
neurological deficits had a bleeding rate of 
1.73 %. A significant three fold increase of 
rebleeding was reported for children, 
female, and deep seated AVM patients. 
The increased risk was highest among this 
group in the first year after initial 
haemorrhage and there after gradually 
reduced.  
Ian. g. Fleetwood et al[33] from Loma 
Linda university studied on cohort of 96 
patients retrospectively with the AVM’s in 
the basal ganglia and thalamus with 
respect to tendency of the lesions to bleed 
between the time of detection and their 
eventual successful management. Mean 
age at diagnosis was 22.7 years and 51% 
were male patients. Intracranial 
haemorrhage was the event leading to 
clinical detection in 71. 9 % of patients 
and 85.5% of these were left with 
hemiparesis. After diagnosis twety five 
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patients had bled a total of 49 times. The 
risk of haemorrhage after detection of an 
AVM of basal ganglia or thalamus was 
9.8% per patient per year. Hence they 
concluded that rate of haemorrhage in 
patients with AVM’s of thalamus and 
basal ganglia are much higher at 9.8% 
compared to avms in other locations [2-
4% per ]year.They also concluded that 
risk of incurring a neurological deficit 
with each haemorrhagic event was high 
hence treatment was recommended for 
these patients. 
At the university of Toronto AVM 
study group assessed patients with large 
and deep AVM’s for their risk of future 
haemorrhage since 1989 and concluded 
that patients with AVM’s large size and 
deep location in the brain were the most 
important and significant factors 
associated with higher risk of future 
hemorrhagic events [31].  
Long-term follow-up study was done 
in an unselected, consecutive patient 
population with AVM’s admitted to the 
Department of Neurosurgery at Helsinki 
University Central Hospital between 
1942 and 2005[50]. Patients with 
untreated AVM’s were followed from 
admission until death, occurrence of 
AVM rupture, initiation of treatment, or 
until the end of 2005. Patients with at 
least 1 month of follow-up were included 
in further analysis. Annual and 
cumulative incidence rates of AVM 
rupture as well as several potential risk 
factors for rupture were analyzed. Two 
hundred and thirty eight patients with a 
mean follow-up period of 13.5 years were 
included (range, 1 month–53.1 years). 
The average annual risk of hemorrhage 
from AVMs was 2.4%. The risk was 
highest during the first 5 years after 
diagnosis, decreasing thereafter. Risk 
factors predicting subsequent AVM 
hemorrhage in univariate analysis were 
young age, previous rupture, deep and 
infratentorial locations, and exclusively 
deep venous drainage. Previous rupture, 
large AVM size, and infratentorial and 
deep locations were independent risk 
factors according to multivariate models.  
Jae H Choi et al[42]; studied on 
morbidity from spontaneous 
haemorrhage of untreated brain 
Arteriovenous malformation. In a group 
of 241 consecutive AVM patients from 
prospective Columbia AVM data bank 
Initially presenting with haemorrhage in 
comparison to 84 non –AVM patients 
with intracerebral haemorrhage from 
Northern Manhattan Study [NOMAS ] 
served as control group, it was concluded 
that Haemorrhage either at initial 
presentation or during follow up of 
untreated AVM’s carried lower morbidity 
than intracranial hemorrhages from other 
causes. 
Retrospective evaluvaton of outcomes 
in 46 unruptured AVM’s & rate for 
bleeding during the follow up period was 
done by Uno masaki et al[28]. In 18 of 22 
patients in grade I & II AVM’s were 
surgically excised and the outcome was 
good. Six of 9 patients in grade IV & V 
were conservatively treated. For patients 
in grade III various treatments were 
performed according to the location of 
the AVM, and their outcomes were 
favourable. Rate of surgical complication 
was 15.3 % in26 unruptured AVM’s. 
Based on this data they concluded to 
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aggressively treat patients with grade I & 
grade II.[uno masaki et.al] 
Crawford P M et al[7] studied on 
unoperated AVM’s with a mean follow up 
of 10.4 years. They concluded That there 
was a 42% risk of haemorrhage, 18% risk 
of epilepsy & 27% risk of neurological 
deficits by 20 years after diagnosis in 
unoperated patients.  
 
 
Figure 1 A 
 
Figure 1 B 
Conclusion 
The behaviour of brain arteriovenous 
malformations (AVMs) remains difficult 
to predict. Host, environmental, and gene 
susceptibility factors may influence the 
clinical manifestation. The complication 
with the most significant clinical sequelae 
is intracranial haemorrhage. 
 
 
Figure 1 C 
Figure 1 MRI and angiography of a patient 
with of unruptured right frontal arteriovenous 
malformation 
(from Emergency Hospital “Prof Dr N Oblu 
”Iasi, Romania, Dr N Dobrin’s collection) 
 
Slowly accumulating data suggest that 
once the process of bleeding starts, the 
lesion appears to become destabilized and 
susceptible to more bleeding [23,24]. 
Therefore, the indication for treatment of 
ruptured AVM’s is generally not under 
dispute. Unruptured AVM’s Whatever 
the treatment technique, the crude 
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proportion of treatment-associated 
morbidity usually ranges around 10% in 
the most recent reports, but this seems 
acceptable given the persistent risk of 
potentially devastating bleeding from an 
untreated AVM. When it comes to 
unruptured brain AVM’s, however, the 
long-assumed benefit of interventional 
therapy seems to have become less clear. 
Current natural history data from the 
Columbia AVM Database, the UCSF 
AVM Study project, and the Scottish 
Intracranial Vascular Malformation Study 
suggest the annual risk of spontaneous 
haemorrhage may be as low as 1% for 
unruptured AVM’s [25,26]. In addition, 
the growing availability of MR imaging 
has led to a substantial increase in the 
incidental detection of unruptured 
malformations ranging between 54% and 
62% of all diagnosed AVM’s in modern 
population-based data-sets [25,26]. In the 
light of these figures, neurovascular teams 
face the clinical dilemma of how to 
balance the inherent risk of intervention 
against the potentially low haemorrhage 
rates in patients harbouring an 
unruptured brain AVM[5] These figures 
raise concern that invasive treatment may 
be connected with an unfavourable 
benefit vs. risk ratio to the degree that 
some have become reluctant to 
recommend interventional therapy for 
many patients presenting with an 
unruptured AVM. Evidence-based 
guidelines give non intervention as one 
option in AVM management [27]. 
Although current clinical practice favours 
intervention in most patients, some 
clinicians understandably prefer to 
undertake intervention in specific 
subgroups of patients who are likely to 
benefit from the intervention. Besides 
haemorrhagic presentation, predictors of 
AVM haemorrhage during natural history 
follow-up include increasing age, deep 
brain location, associated aneurysms, and 
exclusive deep venous drainage [5,10]. By 
contrast, the risk of spontaneous 
haemorrhage may drop below 1% per 
year in AVM’s without these risk factors 
[24]. These characteristics may guide the 
neurovascular team during case 
assessment and patient counselling, but 
the fact that the same factors not only 
increase the natural history risk but also 
the hazard of intervention, clearly adds to 
the complexity. Careful explanation and 
sufficient time is given to patients as be 
the need, because they are often otherwise 
healthy young adults who are actively 
involved in their working and family life. 
 Although data from randomised trials 
to guide the choice of treatment are 
lacking, surgical resection, radiosurgery, 
embolisation, or a combination of these is 
appropriate for AVM’s that are grade I to 
III. The choice of treatment will depend 
on the specific features of the lesion, with 
consideration of the, age of the patient, 
presence or absence of bleeding and 
associated aneurysm, diameter and 
location of associated aneurysms, and 
pattern of venous drainage. Grade I and 
grade II surgery is recommended and 
consideration of endovascular 
embolisation followed by microsurgery is 
recommended for grade III [27]. 
Consideration of radio surgery is 
recommended for lesions that may be 
associated with an increased risk of 
surgical complications, owing to their 
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anatomical location or feeding vessel 
anatomy, in particular for lesions in the 
eloquent area. Grade IV and grade V 
lesions palliate treatment is suggested for 
lesions with intranidal or arterial 
aneurysms or progressive neurological 
deficits related to vascular steal[32]. 
Complete treatment is recommended for 
patients with progressive neurological 
deficits caused by haemorrhage of the 
AVM. [Because of the risks of treatment, 
Grade IV and Grade V lesions are 
generally not treated. American stroke 
association recommendation-2001].  
 Lacking randomized studies on AVM 
treatment, there is considerable 
uncertainty in the existing clinical 
literature on indications for invasive 
treatment in these patients. The best way 
to address the issue is a randomized 
clinical trial. The currently launched A 
Randomized Trial of Unruptured Brain 
AVMs (ARUBA) is a randomized, 
multicenter, international trial comparing 
outcome of invasive AVM treatment with 
conservative management in patients with 
unbled AVM’s. 
ARUBA is investigating whether 
treatment for consenting adults aged ≥18 
years, with an unruptured brain AVM 
that is potentially treatable, over a 
minimum follow up period of five years, 
based on outcome assessments by treating 
physicians. We will have to wait for fresh 
data from this study for enhancing our 
knowledge on management of 
unruptured AVM’s for serving mankind.  
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